Disruptions in care linked to lower short-term survival
Cancer outcomes worsened in the United States during the first two years of the COVID-19 pandemic as routine care was interrupted, according to a report published by Managed Healthcare Executive. The analysis found that one-year cancer survival declined during this period and that the change was associated with an estimated 17,390 additional deaths.
The report connects the rise in deaths to widespread healthcare disruption during 2020 and 2021. During these years, many health systems postponed non-urgent services, patients faced delays in appointments and testing, and treatment schedules were altered as facilities managed COVID-19 caseloads and infection-control measures.
What the report measured
The findings focus on one-year survival, a measure that tracks how many patients are alive one year after a cancer diagnosis. A reduction in one-year survival suggests that more patients died within the first year, which can reflect later-stage diagnosis, delayed initiation of therapy, interruptions in treatment, or limited access to follow-up care.
The report describes the results as a pandemic-era reversal for cancer outcomes, with survival falling and mortality rising compared with expectations in the absence of major disruption to care pathways.
Cancers and groups most affected
Managed Healthcare Executive’s coverage notes that the impact was not uniform. The report identifies differences by cancer type and by population group, indicating that some cancers and some patient communities experienced larger setbacks than others during the disruption period.
While the summary points to variation across cancers and groups, it frames the overall pattern as a system-wide effect of delayed or disrupted services during the pandemic’s first two years.
Why the early pandemic years mattered
The first phase of the pandemic brought multiple barriers that could influence cancer outcomes: reduced screening and diagnostic visits, changes in hospital capacity, staffing constraints, and patient hesitancy about in-person care. These factors can contribute to later detection and delays in starting or completing treatment.
The report links these care interruptions to measurable changes in near-term survival and to the estimated excess deaths.
Key takeaway
The analysis highlights how interruptions in routine cancer services during a public health emergency can translate into worse survival and higher mortality, underscoring the importance of maintaining timely diagnosis and treatment even during healthcare system shocks.